Ciglitazone, PPARgamma agonist
Be the first to review this product! Submit a review
|
(0 Publication)
MW 333.4 Da, Purity >98%. Selective PPARγ agonist (EC50 = 3 μM). Shows antidiabetic and antineoplastic activity. Induces cell cycle arrest and apoptosis. Active in vivo.
View Alternative Names
1,8-cineole 2-exo-monooxygenase, 5 HTT, 5 HTTLPR, 5 hydroxytryptamine (serotonin) transporter, 5 hydroxytryptamine transporter, 5HT transporter, A3AR, A3R, AA3R_HUMAN, ACM3_HUMAN, ACM4_HUMAN, AChR, AD 026, ADA2A_HUMAN, ADORA 3, ADRA2, ADRA2A, ADRA2R, ADRA2RL1, ADRAR, ADRARL1, AI838772, ARA3, AW493413, Adenosine A3 receptor, Adenosine receptor A3, Adrenergic alpha 2A receptor, Albendazole monooxygenase, Albendazole sulfoxidase, Alpha 2 adrenergic receptor subtype C2, Alpha 2AAR subtype C10, Alpha 2B adrenoceptor, Alpha 2B adrenoreceptor, Alpha-2 adrenergic receptor subtype C10, Alpha-2A adrenergic receptor, Alpha-2A adrenoceptor, Alpha-2A adrenoreceptor, Alpha-2AAR, Amine oxidase (flavin containing), Amine oxidase (flavin containing) A, Amine oxidase (flavin containing) B, Antigen NY-CO-13, BAR, BCC7, BXR, Bile acid receptor, CHRM 3, CP33, CP34, CP3A4_HUMAN, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIIA3, CYPIIIA4, Cellular tumor antigen p53, Cholinergic receptor muscarinic 4, Chrm 4, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450-PCN1, D(1A) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor, D-OR-1, D1A dopamine receptor, DADR, DRD 1A, DRD1_HUMAN, Delta type opioid receptor DOR 1, Delta-type opioid receptor, Dopamine D1 receptor, Dopamine D2 receptor, Dopamine D3 receptor, EGBRS, FLJ11090, FLJ92943, Farnesoid X-activated receptor, Farnesol receptor HRR-1, GCN5 general control of amino acid synthesis 5 like 2, GPCR 2, Glucocorticoid inducible P450, HLP, HM 3, HM 4, HRR 1, LFS1, M3 muscarinic receptor, M4, MAO, MAO-A, MAO-B, MGC104252, MGC112732, MGC126680, Monoamine oxidase, Monoamine oxidase A, Monoamine oxidase B, Monoamine oxidase type A, Monoamine oxidase type B, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4, Mutant tumor protein 53, NF 25, NK-2 receptor, NK2R_HUMAN, NKNAR, NR1B1, NR1C3, NR1I2_HUMAN, Na+/Cl- dependent serotonin transporter, Nbor, Neurokinin 2 receptor, Neurokinin A receptor, Neurotransmitter transporter, Nifedipine oxidase, Norepinephrine transporter, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group C member 3, Nuclear receptor subfamily 1 group I member 2, Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, OCD1, ONR 1, OPRD 1, OPRD_HUMAN, OTTHUMP00000058849, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Opioid receptor delta 1, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P450 III steroid inducible, P450 PCN1, P450, family III, P450C3, P53_HUMAN, PAR, PAR q, PPAR-gamma, PPARG2, PPARG_HUMAN, PRR, Peroxisome proliferator activated receptor gamma 2, Peroxisome proliferator-activated receptor gamma, Phosphoprotein p53, Pregnane X receptor, Quinine 3-monooxygenase, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, RIP 14, RP11 552M11.7, RP24-311F12.2, RXR-interacting protein 14, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, Retinoid X receptor-interacting protein 14, SC6A2_HUMAN, SC6A4_HUMAN, SCAN1, SERT, SERT1, SKR, SLC6A5, SXR, Serotonin transporter 1, Seven transmembrane helix receptor, Slc6a2, Slc6a4, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Solute carrier family 6 (neurotransmitter transporter norepinephrine) member 5, Solute carrier family 6 (neurotransmitter transporter) member 4, Solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, Solute carrier family 6 member 4, Solute carrier family 6 member 5, Steroid and xenobiotic receptor, Substance-K receptor, TAC 2R, TAC R2, TACR 2, TACR2, TGPCR1, TRP53, TYDP, TYDP1_HUMAN, Tachykinin receptor 2, Tachykinin receptor 2 (substance K receptor; neurokinin 2 receptor), Taurochenodeoxycholate 6-alpha-hydroxylase, Tp53, Transformation related protein 53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, alpha 2BAR, alpha-2-adrenergic receptor, platelet type, bA552M11.5, cholinergic receptor muscarinic 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, dopamine receptor D1, hSERT, m3 muscarinic acetylcholine receptor, mDOR, muscarinic 3, muscarinic cholinergic m3 receptor, muscarinic m3 receptor, p53 tumor suppressor, pregnane X nuclear receptor variant 2, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, tumor antigen p55
- FuncS
Unknown
Functional Studies - Ciglitazone, PPARgamma agonist (AB141139)
ab19481 staining PPARγ in U-87 MG cells treated with ciglitazone (ab141139), by ICC/IF. Increase of PPARγ cytoplasmic expression correlates with increased concentration of ciglitazone, as described in literature.
The cells were incubated at 37°C for 24 hours in media containing different concentrations of ab141139 (ciglitazone) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab19481 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight® 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
- Chemical Structure
Lab
Chemical Structure - Ciglitazone, PPARgamma agonist (AB141139)
2D chemical structure image of ab141139, Ciglitazone, PPARgamma agonist
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Complementary Products
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com